ÌÇÐÄvlog´«Ã½

Sacral Nerve Stimulation Market Analysis

The Sacral Nerve Stimulation Market is expected to register a CAGR of 5.5% over the forecast period (2022-2027).

The impact of the COVID-19 outbreak on the sacral nerve stimulation market is expected to be significant, as most non-COVID treatment services were disrupted to reserve the healthcare infrastructure for COVID-19-infected patients and minimize the risk of transmission of the SARS-CoV-2 virus. According to a study published in the British Journal of Surgery in May 2020, due to 12 weeks of peak disruption in hospital services due to COVID-19, around 28.4 million elective surgeries worldwide were canceled or postponed and reviews suggest that between 16% to 20% of these surgical procedures constitute of sacral nerve surgical procedures, impacting the sacral nerve stimulation market. Additionally, according to a research study by Jeremy Yuen-Chun Teoh et al., titled " A Global Survey on the Impact of COVID-19 on Urological Services" (2020), globally, the outpatient clinics for female urinary incontinence, benign prostatic hyperplasia, infertility, and sexual medicine, benign scrotal conditions, renal stone, and bladder stone were the most affected by the pandemic. Also, a delay of more than eight weeks for urological services was reported for 28% of all outpatient clinics, 30% of all outpatient investigations and procedures, and 31% of all urological surgeries during the COVID-19 pandemic. Hence, given the facts, the studied market is predicted to be negatively impacted due to the COVID-19 pandemic.

The rising prevalence of overactive bladder conditions and the increasing incidence of urge incontinence, such as urinary tract infection (UTI), are the major drivers for the growth of the market studied. Also, the growing incidence of fecal incontinence and the availability of medical reimbursements are some other factors fueling the market growth. For instance, in 2021, an article titled, 'Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories' reported that globally, urinary tract infection (UTI) was attributed to the most disability-adjusted life-years (DALYs) among the three diseases reported in the article and about 68.89% of individuals were infected with urinary tract infections (UTI) globally during the study period.

Furthermore, the prevalence of urinary incontinence is more in women than in men. For instance, according to a research study by Sedighe Batman et al., published in the BMC Geriatrics Journal in March 2021, the highest prevalence of urinary incontinence was reported to be in older adult women in Asia (45.1%). Some factors influencing the incidence of urinary incontinence in older women are age, obesity, diabetes, hypertension, and smoking. Thus, the growing target patient pool may drive the demand for treatment and promote the sacral nerve stimulation market in the coming years. Furthermore, the rising geriatric population globally is driving the market.

Thus, increasing aging along with growing research investments, and technological advancements associated with the development of novel medical devices are expected to drive the market. However, health risks associated with the devices are expected to slow down the market over the forecast period.

Sacral Nerve Stimulation Market Trends

This section covers the major market trends shaping the Sacral Nerve Stimulation Market according to our research experts:

Sacral Nerve Stimulation in Urinary and Fecal Incontinence Estimated to Witness Growth

Sacral Nerve Stimulation Industry Segmentation

As per the scope of the report, sacral nerve stimulation also referred to as sacral neuromodulation therapy, is a reversible treatment that uses a device to send electrical impulses to sacral nerves that control bladder functions. This treatment is adopted by patients who have fecal and urinary dysfunction. The sacral nerve stimulation market is segmented by Product Type (External Sacral Nerve Stimulation, Implantable Sacral Nerve Stimulation), Application (Urge Incontinence, Urinary, and Fecal Incontinence, Chronic Anal Fissure, and Other Applications), End-Users (Hospitals, Ambulatory Surgical Centers, and Other End-Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.